Name: Name:Benzenesulfonamide, 5-[(2,4-diamino-5-pyrimidinyl)oxy]-2-methoxy-4-(1-methylethyl)-
Brand: Angene
SKU: AG0004UD
Rating: 90 (10 reviews)

Benzenesulfonamide, 5-[(2,4-diamino-5-pyrimidinyl)oxy]-2-methoxy-4-(1-methylethyl)-

CAS No.:

1015787-98-0

Catalog Number:

AG0004UD

Molecular Formula:

C14H19N5O4S

Molecular Weight:

353.3968

Pack Size

Purity

Availability

Location

Price(USD)

Quantity

5mg

99%

1 week

United States

$210

- +

10mg

99%

1 week

United States

$279

- +

25mg

99%

1 week

United States

$501

- +

50mg

99%

1 week

United States

$779

- +

100mg

99%

1 week

United States

$1237

- +

Product Description

Catalog Number:

AG0004UD

Chemical Name:

Benzenesulfonamide, 5-[(2,4-diamino-5-pyrimidinyl)oxy]-2-methoxy-4-(1-methylethyl)-

CAS Number:

1015787-98-0

Molecular Formula:

C14H19N5O4S

Molecular Weight:

353.3968

MDL Number:

MFCD24539325

IUPAC Name:

5-(2,4-diaminopyrimidin-5-yl)oxy-2-methoxy-4-propan-2-ylbenzenesulfonamide

InChI:

InChI=1S/C14H19N5O4S/c1-7(2)8-4-10(22-3)12(24(17,20)21)5-9(8)23-11-6-18-14(16)19-13(11)15/h4-7H,1-3H3,(H2,17,20,21)(H4,15,16,18,19)

InChI Key:

HLWURFKMDLAKOD-UHFFFAOYSA-N

SMILES:

COc1cc(C(C)C)c(cc1S(=O)(=O)N)Oc1cnc(nc1N)N

UNII:

6K6L7E3F1L

Properties

Complexity:

512

Compound Is Canonicalized:

Yes

Covalently-Bonded Unit Count:

Defined Atom Stereocenter Count:

Defined Bond Stereocenter Count:

Exact Mass:

353.116g/mol

Formal Charge:

Heavy Atom Count:

Hydrogen Bond Acceptor Count:

Hydrogen Bond Donor Count:

Isotope Atom Count:

Molecular Weight:

353.397g/mol

Monoisotopic Mass:

353.116g/mol

Rotatable Bond Count:

Topological Polar Surface Area:

165A^2

Undefined Atom Stereocenter Count:

Undefined Bond Stereocenter Count:

XLogP3:

0.7

Literature

Title	Journal
Medicinal chemistry of adenosine, P2Y and P2X receptors.	Neuropharmacology 20160501
P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.	Lancet (London, England) 20150328
Potential for developing purinergic drugs for gastrointestinal diseases.	Inflammatory bowel diseases 20140701
The therapeutic promise of ATP antagonism at P2X3 receptors in respiratory and urological disorders.	Frontiers in cellular neuroscience 20130101

Properties